All In Biotech

Drug Trial Radar · NCT06790862

A Trial of SHR0302Base in Patients With Vitiligo

A Multicenter, Randomized, Double-blind, Parallel, Excipient-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SHR0302Base in Subjects With Nonsegmental Vitiligo

Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 155 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

155

Actual

Start

Feb 13, 2025

Primary completion

Mar 3, 2026

Study completion Apr 2026

Sponsor

Sponsor type
Industry
First posted
Jan 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of SHR0302Base in participants with nonsegmental vitiligo.

Conditions

  • Vitiligo

Interventions

  • SHR0302Base gelDrug

    SHR0302Base gel.

  • SHR0302Base gel placeboDrug

    SHR0302Base gel placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects who achieved at least a 50% improvement from baseline in the facial-neck vitiligo area score (F-VASI 50 response).Time frame: At week 24.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital affiliated to Shandong First Medical University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.